throbber
UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`
`AMNEAL PHARMACEUTICALS, LLC and
`PAR PHARMACEUTICAL, INC
`Petitioners
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner
`
`
`
`_____________________
`
`CASE IPR2015-00554
`Patent 7,668,730
`_____________________
`
`PETITIONERS’ REPLY REGARDING THE IDENTIFICATION OF REAL
`PARTIES IN INTEREST
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`
`

`
`
`
`TABLE OF CONTENTS
`
`IPR2015-00554
` Patent No. 7,668,730
`
`I.
`INTRODUCTION ........................................................................................... 1
`LEGAL STANDARD ..................................................................................... 1
`II.
`FACTUAL BACKGROUND .......................................................................... 2
`III.
`IV. THE PETITIONS CORRECTLY IDENTIFY PAR INC. AS THE
`REAL PARTY IN INTEREST. ....................................................................... 3
`A. None of the Par Parents Have a Tangible Interest in the
`Petitions. ................................................................................................. 4
`Par Inc. Has Exercised Sole Direction and Control Over the
`Petitions. ................................................................................................. 5
`1.
`The Board Has Found the Type of Evidence Jazz
`Presents Here Insufficient to Confer RPI Status on a
`Non-Party. ................................................................................... 5
`Prior Board Decisions Finding Non-Party Parent
`Companies To Be RPIs Are Distinct From the Present
`Case. ............................................................................................ 8
`CONCLUSION .............................................................................................. 10
`
`B.
`
`2.
`
`V.
`
`-i-
`
`
`
`
`
`

`
`IPR2015-00554
` Patent No. 7,668,730
`
`I.
`
`INTRODUCTION
`
`Pursuant to the Board’s Order on May 12, 2015 (Paper 11), Petitioner Par
`
`Pharmaceutical, Inc. (“Par Inc.”) hereby responds to Jazz Pharmaceuticals, Inc.’s
`
`(“Jazz”) assertion that the above-captioned petition for inter partes review failed to
`
`name Par Inc.’s direct and indirect parent holding companies as “real parties-in-
`
`interest” (“RPI”). The Board should reject Jazz’s arguments as they fail to establish
`
`that Par Inc.’s parent holding companies have an interest in or control over this
`
`proceeding sufficient to render them RPIs.
`
`II. LEGAL STANDARD
`The patent owner challenging a Petitioner’s RPI disclosure must provide
`
`sufficient evidence to show the disclosure is inadequate. Intellectual Ventures
`
`Mgmt, LLC v. Xilinx, Inc., IPR2012-00018, Paper 12 at 3 (P.T.A.B. Jan. 24, 2013).
`
`The RPI is “the party that desires review of the patent”—that is, the party “at
`
`whose behest the petition has been filed.” Office Patent Trial Practice Guide, 77
`
`Fed. Reg. 48,756, 48,759 (Aug. 14, 2012) (to be codified at 37 C.F.R. Pt. 42). The
`
`RPI requirement exists to ensure that a non-party is not “litigating through a
`
`proxy.” See Aruze Gaming Macau, Ltd. v. MGT Gaming, Inc., IPR2014-01288,
`
`Paper 13, at 12 (P.T.A.B. Feb. 20, 2015). Moreover, the RPI analysis is a narrowly
`
`tailored inquiry into the “relationship between a party and a proceeding;” not “the
`
`relationship between parties.” Id. at 11.
`
`
`
`-1-
`
`

`
`The mere existence of a parent-subsidiary relationship “does not establish a
`
`IPR2015-00554
` Patent No. 7,668,730
`
`
`
`relationship sufficient to make the parent a real party in interest.” TRW Automotive
`
`U.S. LLC v. Magna Elec. Inc., IPR2014-01499, Paper 7 at 11 (P.T.A.B. Mar. 19,
`
`2015). Instead, Patent Owner must sufficiently demonstrate with evidence that the
`
`parent controls a subsidiary’s participation in the inter partes review. Compass
`
`Bank v. Intellectual Ventures II, IPR2014-00719, Paper 11 at 8 (P.T.A.B. Oct. 24,
`
`2014).
`
`III. FACTUAL BACKGROUND
`Par Inc. is the wholly-owned subsidiary of a series of holding companies,
`
`including Par Pharmaceutical Companies, Inc. (“Par Co.”); Sky Growth
`
`Intermediate Holdings II, Inc. (“SGIH II”); Sky Growth Intermediate Holdings I,
`
`Inc. (“SGIH I”); and Par Pharmaceutical Holdings, Inc. (“Par Holdings”)
`
`(collectively, the “Par Parents”). (PAR1040, ¶2.) Par Inc. is engaged in the
`
`business of making, selling and distributing pharmaceuticals; the Par Parents,
`
`however, do not conduct any such operations. (Id., ¶¶ 2–4.)
`
`Par Inc. prepared and filed ANDA No. 205403 (“Par’s ANDA”) with the
`
`United States Food and Drug Administration, directed to a 500 mg/ml solution of
`
`sodium oxybate (“Par’s ANDA Product”), and holds all right and title to that
`
`ANDA (Id., ¶5.) Par’s ANDA includes “Paragraph IV” certifications that U.S.
`
`Patent Nos. 7,668,730; 7,765,106; 7,765,107; 7,895,059; 8,457,988; and 8,589,182
`
`-2-
`
`

`
`
`(collectively, “the Petition Patents”) are invalid or would not be infringed by Par’s
`
`IPR2015-00554
` Patent No. 7,668,730
`
`ANDA Product. Based on that ANDA filing, Jazz sued Par Inc.—and, after nearly
`
`eighteen months of litigation, has yet to sue any of the Par Parents—for
`
`infringement of the Petition Patents, among others, and seeking a declaration that
`
`Par’s ANDA Product would infringe them upon FDA approval. (See PAR1026 at
`
`16–23.)
`
`IV. THE PETITIONS CORRECTLY IDENTIFY PAR INC. AS THE
`REAL PARTY IN INTEREST.
`
`Far from being a “nominal plaintiff” with “no substantial interest,” Par Inc.
`
`is the only Par entity with a cognizable interest in these Petitions, and is the only
`
`Par entity that has maintained any control over their preparation and filing.1 Jazz
`
`has failed to offer credible evidence that Par Inc. is acting as a proxy for the Par
`
`Parents, or that the Par Parents control these Petitions so as to render them RPIs.2
`
`
`1 Amneal Pharmaceuticals LLC, of course, is also an RPI with respect to
`
`IPR2015-00545, -00546, -00547, and -00554.
`
`2 Notably, Jazz named Jazz Pharmaceuticals, Inc. as the sole RPI in its
`
`Mandatory Notices, (see Paper 8 at 2) despite Jazz being a wholly-owned
`
`subsidiary of Jazz Pharmaceuticals PLC, which could presumably control or direct
`
`its behavior in these proceedings as well for the same reasons. (See PAR1041 at 29
`
`-3-
`
`

`
`
`
`IPR2015-00554
` Patent No. 7,668,730
`
`A. None of the Par Parents Have a Tangible Interest in the Petitions.
`Whether the Par Parents are RPIs depends on the relationship between them
`
`and these inter partes review proceedings, not their relationship to Par Inc. See
`
`Aruze Gaming, IPR2014-01288, Paper 13 at 12. Fundamental to that inquiry is the
`
`non-party’s interest in the proceeding, and whether it has an opportunity to control
`
`that proceeding to see that interest carried out. See Office Patent Trial Practice
`
`Guide, 77 Fed. Reg. at 48,759 (“[A]t a general level, the ‘real-party-in-interest’ is
`
`the party that desires review of the patent.”) Jazz would turn that inquiry on its
`
`head: Jazz would have the Board conclude the Par Parents are RPIs solely from
`
`their ability to control Par Inc., without showing that they have in fact exercised
`
`control or what the Par Parents’ interest is.
`
`Par Inc., on the other hand, prepared, filed, and owns its ANDA. (PAR1040,
`
`¶5.) After eighteen months of litigation, Jazz has only sued Par Inc., and none of
`
`the Par Parents, for infringement. (Id., ¶6; see also PAR1026.) Par Inc. is the only
`
`Par entity that directed, controlled, and funded the preparation and filing of these
`
`Petitions. (Id.) If the Petitions are ultimately successful, Par Inc. will have cleared
`
`one obstacle towards approval of its ANDA. The Par Parents, however, have no
`
`interest in seeking review of the Petition Patents. (PAR1040, ¶8). Thus, other than
`
`and Exhibit 21.1.) In other words, even Jazz apparently does not believe that a
`
`parent-subsidiary relationship alone is enough to make a corporate parent an RPI.
`
`-4-
`
`

`
`
`those for which Amneal Pharmaceuticals LLC is a Petitioner, Par Inc. is the sole
`
`IPR2015-00554
` Patent No. 7,668,730
`
`RPI for these Petitions.
`
`B.
`
`Par Inc. Has Exercised Sole Direction and Control Over the
`Petitions.
`
`Because Jazz cannot demonstrate that the Par Parents have an actual,
`
`cognizable interest in these proceedings, Jazz’s argument is reduced to a series of
`
`superficial observations regarding the corporate ownership of Par Inc., rather than
`
`an actual showing that the Par Parents had the opportunity or relevant reason to
`
`direct or control the instant proceedings.
`
`1.
`
`The Board Has Found the Type of Evidence Jazz Presents
`Here Insufficient to Confer RPI Status on a Non-Party.
`
`Jazz claims that Par Inc. and the Par Parents “hold themselves out as a single
`
`unit,” relying heavily on public financial documents that include collective
`
`references to Par Inc. and the Par Parents through words such as “we,” “our,” and
`
`“the Company” Paper 10 at 13. But using these generic descriptors in such
`
`documents is commonplace. The Board has rejected attempts to base RPI status on
`
`such “generic references to the existence of a parent/subsidiary relationship in SEC
`
`documents.” TRW Auto., IPR2014-01499, Paper 7 at 11. The Board has similarly
`
`declined to parse the semantics of public statements for evidence of a non-party
`
`RPI. See id. at 9, 11 (finding use of “the Company” in press releases insufficient).
`
`That Par Inc. and the Par Parents operate a single website also is irrelevant.
`
`-5-
`
`

`
`
`First, the Board has previously held that a shared website between sister companies
`
`IPR2015-00554
` Patent No. 7,668,730
`
`did not make the non-party an RPI. See Aruze Gaming, IPR2014-01288, Paper 13
`
`at 17–18. Second, none of the Par Parents conduct any operations; Par Inc. is the
`
`Par entity that manufactures, sells, and distributes drugs. (PAR1040 at ¶¶3–4.) That
`
`Par Inc. is a subsidiary to the Par Parents makes it no different than the situation in
`
`Aruze; Jazz attempts to elevate form over substance and says nothing regarding the
`
`Par Parents’ relationship to these Petitions.
`
`Jazz further asserts that Par Inc. and the Par Parents “act as a single unit”
`
`and “are controlled by a single master,” Paper 10 at 13. But, even if true, the Board
`
`has found such parent/subsidiary relationships inadequate to show “sufficient
`
`opportunities to control all aspects of Petitioner’s business, including controlling
`
`this inter partes review,” for purposes of establishing a parent corporation as an
`
`RPI. TRW Auto., IPR2014-01499, Paper 7 at 9 (quotation marks omitted).
`
`Similarly, that Par Inc. shares corporate officers with the Par Parents does not
`
`mean the Par Parents control Par Inc. in this proceeding, or have the ability to do
`
`so. See Butamax Advanced Biofuels LLC v. Gevo, Inc., IPR2013-00215, Paper 47
`
`at 6 (P.T.A.B. Sept. 23, 2014) (finding that Board membership of two directors in
`
`both parent and subsidiary insufficient to make the parent an RPI).
`
`More fundamentally, however, Jazz misses the mark because it aims for the
`
`wrong target: “RPI does not describe the relationship between parties” but the
`
`-6-
`
`

`
`
`“relationship between a party and a proceeding.” Aruze Gaming, IPR2014-01288,
`
`IPR2015-00554
` Patent No. 7,668,730
`
`Paper 13 at 11. Par Inc. was the sole party responsible for directing, controlling,
`
`and funding the preparation and filing of the Petitions. (PAR1040, ¶7.) None of the
`
`Par Parents participated in the decision to file the Petitions, nor did they exercise
`
`any control over the filing or content of the Petitions, nor did they provide funding
`
`or other compensation for the preparation and filing of the Petitions. (Id.) The
`
`Petitions were not discussed at any of the Par Parents’ board meetings. (Id.) The
`
`opportunity for control was simply not present.
`
`Yet Jazz points to public statements by two of Par Inc.’s parent companies
`
`referring to the related district court litigation as “our legal proceedings.” Paper 10
`
`at 19. But simply because Par Holdings and Par Co. refer to themselves and their
`
`wholly-owned subsidiary in the first-person plural is hardly “telling”3 that Par
`
`Holdings and Par Co. intend to defend against Jazz’s enforcement of its patents. in
`
`light of the fact that—after eighteen months of litigation—Jazz has not named the
`
`
`3 Likewise, Jazz’s latest 10-K states “[i]n this report, unless otherwise indicated or
`
`the context otherwise requires, all references to ‘Jazz Pharmaceuticals,’ ‘the
`
`registrant,’ ‘we,’ ‘us,’ and ‘our’ refer to Jazz Pharmaceuticals plc and its
`
`consolidated subsidiaries.” (see PAR1041 at 3), despite the fact that Jazz never
`
`named Jazz Pharmaceuticals plc as an RPI.
`
`-7-
`
`

`
`
`Par Parents as defendants, nor have the Par Parents intervened in those litigations
`
`IPR2015-00554
` Patent No. 7,668,730
`
`or filed declaratory judgments on any of the Petition Patents. (PAR1040, ¶8.)
`
`Second, Jazz relies on the LinkedIn page of David Silverstein—the attorney
`
`who signed the power-of-attorney for the instant petitions—to show he is
`
`employed by Par Co. But, in fact, David Silverstein is, in fact, employed on behalf
`
`of Par Inc. (id., ¶7) and signed the Power of Attorney on Par Inc’s behalf. (See
`
`Paper 3). And while Jazz cites two pleadings showing Par Inc.’s outside counsel
`
`are also litigation counsel for Par Co. in unrelated proceedings, using common
`
`litigation counsel hardly makes a non-party an RPI. See Aruze Gaming, IPR2014-
`
`01288, Paper 13 at 19. Thus, Jazz offers no credible evidence of a relationship
`
`between the Par Parents and these Petitions—much less control over them.
`
`2.
`
`Prior Board Decisions Finding Non-Party Parent
`Companies To Be RPIs Are Distinct From the Present Case.
`
`The Board has previously found a petitioner’s parent corporation to be an
`
`RPI in certain proceedings where “the parent corporation ‘has had control, or could
`
`have controlled the petitioner, in all aspects of its business,’ which would include
`
`… the inter partes review.” TRW Auto., IPR2014-01499, Paper 7 at 10 (quoting
`
`Zoll Lifecor Corp. v. Philips Elecs. N. Am. Corp., IPR2013-00609, Paper 15 at 12
`
`(P.T.A.B. Mar. 20, 2014)). But each of those cases involved a situation where a
`
`Petitioner’s parent stood to gain or lose financially from an underlying patent
`
`-8-
`
`

`
`
`infringement suit. See Atlanta Gas Light Co. v. Bennett Regulator Guards, Inc.,
`
`IPR2015-00554
` Patent No. 7,668,730
`
`IPR2013-00453, Paper 88 at 3 (P.T.A.B. Jan 6, 2015); Zoll, IPR2013-00609, Paper
`
`15 at 11–12; Galderma S.A. v. Allergan Industrie, IPR2014-01422, Paper 14 at 12–
`
`13 (P.T.A.B. Mar. 5, 2015). That situation is not present here: the Par Parents have
`
`no direct interest in these proceedings. (PAR1040, ¶8.)
`
`Moreover, in those cases, the Petitioner’s parent showed a greater degree of
`
`control over the subject matter of the Petitions than can be shown here. In Zoll, the
`
`Patent Owner provided evidence showing “unified actions by Petitioner and
`
`[parent company] in [a] ‘multi-state patent war’ … with Patent Owner,” and
`
`highlighting
`
`that
`
`the non-party parent’s management
`
`team—rather
`
`than
`
`petitioner’s—participated in a court-ordered mediation in a related proceeding.
`
`Zoll, IPR2013-00609, Paper 15 at 12. Similarly, in Atlanta Gas, the crucial finding
`
`was that officers for the parent engaged in related negotiations on behalf of both
`
`the Petitioner and its parent regarding triggering indemnity provisions in
`
`connection with the patent litigation. IPR2013-00453, slip op., Paper 88 at 9–10
`
`(P.T.A.B. Jan. 6, 2015). In Galderma, the Board found “historical evidence for a
`
`pattern of control” of the parent over the subsidiary with respect to the specific
`
`products at issue in a parallel patent suit. See IPR2014-01422, Paper 14 at 11–12
`
`(while also noting “the existence of a parent-subsidiary relationship alone” is
`
`insufficient to show RPI status. Id. at 12.)
`
`-9-
`
`

`
`None of these facts are present here. Rather, Jazz relies on allegations that
`
`IPR2015-00554
` Patent No. 7,668,730
`
`
`
`the “same corporate officers… control the decision making for all of the Par
`
`companies as a whole,” Paper 10 at 16, without evidence that those corporate
`
`officers directed or controlled these Petitions or the litigation. And Jazz has offered
`
`no basis to conclude that these corporate officers would have directed or controlled
`
`these Petitions or the litigation in their role as officers for the Par Parents. Jazz
`
`alleges nothing more than the existence of parent holding companies above Par
`
`Inc., which is insufficient to warrant a judgment that the Par Parents are RPIs.
`
`V. CONCLUSION
`The evidence shows Par Inc. is the only Par entity that has funded, directed,
`
`or controlled these inter partes reviews. Jazz’s claims amount to nothing more than
`
`generic references to a traditional parent-subsidiary relationship. Par Inc. has thus
`
`fully satisfied the requirements of § 312(a) and the Board should maintain the
`
`current Petition filing dates and institute review of the Petition Patents.
`
`Respectfully Submitted,
`
`Date: May 26, 2015
`Arent Fox LLP
`
`1717 K Street NW
`Washington, DC 20006
`202.857.6000
`
`
`
`
`
`
`
`
`
`Aziz Burgy
`Registration No. 51,514
`Attorney for Petitioner
`
`
`
`-10-
`
`

`
`CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e))
`
`IPR2015-00554
` Patent No. 7,668,730
`Certificate of Service
`
`
`The undersigned hereby certifies that the above-captioned “Petitioners’
`
`Reply Regarding the Identification Of Real-Parties-in-Interest” including its
`
`supporting evidence (EXHIBITS PAR1040-1041), was served in its entirety on
`
`May 26, 2015 by filing these documents through the Patent Review Processing
`
`System, as well as e-mailing copies to the following:
`
`F. Dominic Cerrito
`Eric C. Stops
`Gabriel P. Brier
`QUINN EMANUEL URQUHART &
`SULLIVAN LLP
`51 Madison Avenue
`22nd Floor
`New York, NY 10010
`nickcerrito@quinnemanuel.com
`
`
`
`John V. Biernacki
`JONES DAY
`North Point
`901 Lakeside Avenue
`Cleveland, OH 44114
`jvbiernacki@jonesday.com
`
`
`
`
`
`Additional addresses known to
`Petitioner as likely to effect service
`
`
`
`
`
`

`
`
`
`IPR2015-00554
` Patent No. 7,668,730
`Certificate of Service
`
`
`Respectfully Submitted,
`
`Aziz Burgy
`Registration No. 51,514
`Attorney for Petitioner
`
`
`
`
`
`
`
`Date: May 26, 2015
`ARENT FOX LLP
`1717 K Street, NW
`Washington, DC 20006
`202.857.6000

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket